Limba
|
Bimiralisib (PQR309) is a novel brain-penetrant dual PI3K/mTORinhibitor with in vitro and in vivo antilymphoma activity. It displays excellent selectivity versus PI3K-related lipid kinases, protein kinases and unrelated targets.
| Price | 992,00 RON (preturile sunt fara TVA) |
|---|---|
| Description |
Bimiralisib (PQR309) is a novel brain-penetrant dual PI3K/mTORinhibitor with in vitro and in vivo antilymphoma activity. It displays excellent selectivity versus PI3K-related lipid kinases, protein kinases and unrelated targets. |